Sarah Collins
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Sarah Collins
How Does UNH’s Valuation Look in October?
UnitedHealth Group is a leading managed healthcare firm in the United States.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Boston Scientific Stock Up Today on the Acquisition of Veniti
Boston Scientific (BSX) announced the acquisition of Veniti for $108.0 million. BSX already owns a 25% stake in Veniti.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.
Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?
In its Structural Heart business, Abbott Laboratories reported 1Q18 sales of $0.29 billion, registering YoY organic sales growth of 7.5%.
How Johnson & Johnson Plans to Restore Women’s Health Sales
Johnson & Johnson (JNJ) reported sales of $3.4 billion in its consumer business in the first quarter, with 7% of it from its women’s health business.
Medtronic’s Key Growth Driver: MiniMed 670G Hybrid Closed Loop
Medtronic’s Diabetes Group performance in fiscal Q4 2018 was driven by a 25% growth for its MiniMed 670G hybrid closed-loop insulin pump.
Why NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis
On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE.
Johnson & Johnson’s Growth Strategy: Expand Emerging Channels
Amid the increasing presence of digital technology, Johnson & Johnson (JNJ) has recognized the need to expand its channel presence.
What’s behind Biogen Buyout Rumors?
Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.
Varian’s Halcyon Treatment System Sees Emerging Market Demand
Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]
TMO’s Oncomine Target Test Launch Will Boost This Business
On June 27, 2017, Thermo Fisher Scientific announced the launch of its Oncomine Dx Target Test.
Johnson & Johnson’s Over-the-Counter Growth through Innovation
In its fiscal first quarter, Johnson & Johnson (JNJ) registered sales of $1.1 billion for its OTC (over-the-counter) business.
How Are Stryker’s Core Strategies Working Toward Its Growth?
Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.
Teva’s Granix Gets FDA Approval for Expanded Indication
Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.
Align Technology Traded at Its 52-Week High in September
Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.
WTX101: A Superior Treatment for Wilson Disease
WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.
Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.
Competition Dynamics for Ajovy—Teva’s Migraine Drug
Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.
Non-Opioid Pain Therapy Market Opportunity for Teva
The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
Johnson & Johnson’s Erleada Approved by Health Canada
On July 4, Johnson & Johnson’s (JNJ) pharmaceuticals division, Janssen, received Health Canada’s approval for its drug Erleada.
Innovative Products Driving Medtronic’s Growth
Medtronic expects its MITG segment to have an organic growth rate of 4% in fiscal 2019.
Johnson & Johnson in the Changing Consumer Market Landscape
Although changing consumer market dynamics pose challenges for Johnson & Johnson (JNJ), it’s confident it will be able to adapt.
Wall Street Looks at Sales Forecasts for Mylan’s Fulphila
According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.
How Has Boston Scientific Stock Performed Recently?
Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.
How Johnson & Johnson’s Partnerships Enhance Customer Value
Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.
Analyst Recommendations for Varian Medical Systems before 1Q18
Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. It wants to establish itself as the leading cancer management company in the world.
Mylan’s Humira Biosimilar Opportunity in Europe
On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.
A Brief Look at Abbott’s Alere Integration Progress and Recovery
Alere’s integration synergies in 1Q18 were delivered through strong performance of the company’s Rapid Diagnostics business.
How Is UNH’s Optum Business Positioned in the Industry?
UnitedHealth Group is, by revenue, the largest healthcare company in the world.
Discussing Abbott’s Market Position and Growth Prospects in China
China contributes significantly to Abbott’s Established Pharmaceuticals division, which registered sales of ~$1.1 billion, representing year-over-year growth of ~10.0%.
A Look at Teva’s Generic Drugs Research Pipeline
Teva Pharmaceutical Industries has the largest generics product pipeline in the industry. It has 325 applications that are awaiting FDA approval.
Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.
Johnson & Johnson’s Strategy to Broaden Scope of Innovation Model
Johnson & Johnson (JNJ) is focused on growth driven by innovation, which has led to new categories or enhanced standards of care.
Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth
On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.
Teva’s Copaxone Maintains Market Share amid Intense Competition
In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.
Teva’s Austedo Sales Continue to Gain Momentum in 2018
In 1Q18, Teva Pharmaceutical (TEVA) reported sales of $30 million from the sales of its Austedo drug.
Teva’s Key Drugs in Its Specialty Products Pipeline
Teva’s Austedo, approved by the FDA in April 2017, is one of the company’s major growth drivers.
BIIB Stock Tumbles as Alzheimer Drug BAN2401 Data Failed to Impress Investors
Today, Biogen (BIIB) and partner Eisai presented highly anticipated detailed study data for their investigational Alzheimer’s drug BAN2401.
A Brief Recap of the Abbott–Alere Deal Developments
Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.
How BD-Bard Acquisition Will Strengthen International Presence
C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.
Teva Announces First-to-File Launch of Generic Cialis
Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.
These Developments Impacted Abbott Laboratories the Most in Fiscal 2017
Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.
How Stryker’s Margins Are Driven by Its CTG Program
Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.
ABT Expands in Europe with Freestyle Libre 2 Approval
On October 1, ABT announced that it had received a CE mark in Europe for its next-generation continuous glucose monitoring system, the Freestyle Libre 2.
Sanofi’s Organizational Restructuring: Investor Insights
On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.
Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.
